Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains how AI is integrated into pharmaceutical development.
News|Articles|November 2, 2003
- Pharmaceutical Technology-11-02-2003
- Volume 27
- Issue 11
FDA Will Drive Changes for Contract Business
Author(s)Jim Miller
As FDA tries to bring pharmaceutical manufacturing into the 21st century, competitive dynamics in contract manufacturing are likely to change in favor of companies that have greater manufacturing expertise and the means to invest in new technologies.
Advertisement
Articles in this issue
almost 23 years ago
In the Spotlight--Decemberalmost 23 years ago
Novemember 2003almost 23 years ago
FDA Seeks Risk-Based Inspection Programalmost 23 years ago
Routine Sample Size for a Retest Procedurealmost 23 years ago
November 2003almost 23 years ago
Clearing Regulatory Hurdlesalmost 23 years ago
Improving Protein Capture for Transgenic Drug ProcessingAdvertisement
Related to this article
Shilpa Pharma Lifesciences Limited will launch a new small-molecule CDMO at CPHI Milan in October.
This article explains the 4 shifts enabling faster, lower-risk, commercially successful biologics technology transfer.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Risk-Based Life Cycle Management of Master Production and Control Records to Strengthen Data Integrity and GMP Inspection Readiness Part 2: Practical Considerations for CGMP Documentation Systems
2
PharmTech’s Weekly Roundup—September 25, 2026
3
CPHI Milan: USP Benchmarks Reshape Procurement Incentives
4
PharmTech AI Pulse Check: Validating Multi-Agent Systems, OCR Models in GxP
5